SHPK and chronic myelogenous leukemia, BCR-ABL1 positive: SHK could overcome resistance of CML cells to tyrosine kinase inhibitors (TKI) by downregulation of miR-92a-1-5p, a poor-prognosis marker frequently overexpressed in patients with leukemia (Huang et al., 2020).